IDEXX LABORATORIES INC /DE (IDXX)

IDEXX Laboratories, incorporated in Delaware in 1983, develops, manufactures, and distributes diagnostic products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries, and also provides human medical point-of-care and laboratory diagnostics. The company operates through three reportable segments—Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD)—plus an Other segment combining its OPTI Medical human diagnostics business and out-licensing arrangements. CAG, the largest segment, offers in-clinic diagnostic instruments and consumables (including the Catalyst, ProCyte, SediVue Dx, and SNAP rapid assay lines, many incorporating proprietary AI), outside reference laboratory diagnostic and consulting services through roughly 80 labs worldwide, veterinary practice management software (ezyVet, Cornerstone, Animana, IDEXX Neo), cloud-based diagnostic information management (VetConnect PLUS, DecisionIQ), and diagnostic imaging systems (ImageVue, IDEXX-PACS, Web PACS).

The Water segment provides microbiological water testing products such as Colilert, Enterolert, Pseudalert, Legiolert, and Quanti-Tray systems used to detect contaminants like E. coli, coliforms, and Legionella in drinking, recreational, and wastewater. The LPD segment supplies diagnostic tests and instruments for livestock and poultry disease detection (e.g., BVDV, PRRS, ASFV) and dairy antibiotic residue testing (SNAP Beta-Lactam, SNAPduo). The Other segment includes OPTI Medical's point-of-care human blood gas and electrolyte analyzers used in hospitals, plus efforts to commercialize proprietary drug delivery IP.

IDEXX markets globally through direct sales forces and distributors, competing with companies such as Mars/Antech/Heska, Zoetis, Covetrus, FUJIFILM, and major human diagnostics firms like Roche and Abbott. The company relies on numerous sole/single-source suppliers, including a key agreement with Ortho for Catalyst chemistry slides through 2033, and maintains ISO-certified manufacturing facilities in Maine, Georgia, Tennessee, and several European countries. Its products are subject to extensive regulation by the FDA, USDA/APHIS, EPA, and international equivalents, covering veterinary devices, water testing methods, dairy testing, and human diagnostic devices, as well as chemical and environmental rules such as REACH, RoHS, and emerging PFAS regulations.

R&D expenses were $191.0 million (5.2% of revenue) in 2023, $254.8 million (7.6%) in 2022, and $161.0 million (5.0%) in 2021. As of December 31, 2023, IDEXX employed approximately 11,000 full- and part-time workers, with a stated commitment to diversity, equity, and inclusion initiatives.